A message from CEO
“molmir” is a coined word with the meaning of looking at molecules. By capturing the movement of molecules at the atomic level, we will develop treatment methods for intractable diseases including ALS (amyotrophic lateral sclerosis). We will develop treatment methods for intractable diseasesincluding ALS and present new possibilities for drug discovery from Japan to the world.
Eiichiro Mori
June 21, 2022
Venture from Academia（3 institutional accreditations）
Mormil Co., Ltd. is a venture company certified by Nara Medical University, National Institute of Advanced Industrial Science and Technology, AIST, and Tokushima University. They were registered as accredited ventures in June 2022 (No. 5), July 2022 (No. 153), and August 2022 (No. 31), respectively. In the future, we will continue to cooperate with various research institutes and aim to stand as a “human resource platform (infrastructure/receptacle) for Japanese science and technology”.
A member list（January 13, 2023）
Eiichiro Mori （CEO・Nara Medical University） Masataka Yamamoto（COO） Kota Togami （CFO） Shunsuke Tomita （Scientific Advisor・AIST） Tomohide Saio （Scientific Advisor・Tokushima University）
News
- CEO Dr. Mori will pitch at the Demo Day by Rising Biotech Challenge
- molmir was interviewed at the Kansai Startup Night Vol.6 by kr36
- Drug development platformer molmir raised fund to observe inter molecular dynamics
- molmir raised funds, aiming to build a new drug discovery platform with the technology of “detecting the molecules dynamics.”
- About our logo and vision